Finally, the MYCN transcriptional activation pathway reflects MYCN-driven oncogenic transcriptional programs, which define an aggressive subset of IDH-wildtype gliomas characterized by high proliferation, metabolic reprogramming, and poor prognosis (Borgenvik et al., 2021; Zhou et al., 2023). The gene discussed is MYCN; the disease is central nervous system cancer.